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 Pichia pastoris has demonstrated the ability to express high levels of recombinant 
heterologous proteins. Protein expression is enhanced during fermentation at high cell 
density. However, the level of expression is mainly regulated by fermentation operation 
factors. This research is directed to investigate the effect of methanol growth rate, 
temperature and pH in the expression of the total 5P12-Rantes concentration, expression 
of active 5P12-Rantes and Specific yield using the response surface methodology and 
central composite design. 
 The response surface methodology, RSM, has been used successfully used by 
Zhang, W. and Ian, M. to optimize the cell density and fermentation process. The RSM is 
equipped with statistical tools to determine the significance of a factor over a response. 
The evaluation of factors using the RSM uses experimental design in order to distribute 
the selected variables within the boundaries of the design.  
The central composite design, CCD, allows allocation of Methanol growth rate, 
temperature, and pH to evaluate their effect in the expression of 5P12-Rantes. The effect 
of methanol growth rate is evaluated from a minimum value of 0.01 h-1 to a maximum of 
0.4 h-1, 24.06 °C to 29.94 °C for temperature and 1.99 to 4.51 for pH.  
 The methanol growth rate has demonstrated to have no effect in any of the 
responses. In contrast, Temperature and pH has a significant effect in all the responses. 
However, the lack of fit of the proposed model doesn’t allow good estimations of 
predicted responses. In order to minimize the lack of fit of the propose models, the 
methanol growth rate has been excluded from all the three models. A new 2 factor second 
order model is proposed to analyze the significance of temperature and pH. The lack of 
fit decreased and the optimal operating conditions for temperature and pH was 
determined at 27.14 °C and 3.16 which results in a maximum of 26.52 g/L of active 
5P12-Rantes and 0.16 mg Rantes/g dry cell. 
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CHAPTER I 
LITERATURE REVIEW 
ABSTRACT  
The characterization of the HIV-1’s envelope proteins has provided an abundant 
knowledge about the viral structure conformation. However, the discovery of the 
infection mechanism has made possible the development of drugs to prevent HIV-1 
infection. The sequence of HIV-1 infection is mainly characterized by a series of 
conformational modifications in the viral envelope proteins. These modifications direct 
the interaction of the virus with the target cell and thereafter the delivery the RNA viral 
information.   
Human cells express an incredible variety of proteins directed to protect them 
against diseases. For example, Regulated-on-Activation-Normal-T-cells-Expressed-and-
Secreted, RANTES, has chemoattractant activity for monocytes and it is expressed in 
response to viral infection. This protein is expressed by the immune cells called cytotoxic 
phenotype CD8+ and the helper CD4+ T cell in response to the detection of a foreign 
microorganism. Unfortunately, in the case of HIV-1, the expression of RANTES occurs 
after the cells have been infected by the virus.  
The development of effective therapies to protect against HIV-1 viral infection 
has focused upon the design of drugs with the capability to interfere with the infection 
mechanism. For example, 5P12-Rantes, a homologous of human RANTES, has proved 
protection against HIV-1 infection by competitive interaction with the co-receptor CCR5. 
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The chapter discusses the HIV-1 entry mechanism and describes the 
conformational modifications of the viral envelope proteins. The functional activity of the 
5P12-Rantes is described as part of viral entry inhibition.  
INTRODUCTION 
HIV-1 Entry Mechanism 
The HIV-1entry mechanism depends on the sequential interaction of the virion 
envelope glycoproteins 120 and 41 (gp120 and gp41) with cellular receptor cluster of 
differentiation (CD4) and co-receptor chemokine type 5 or CCR5 (Rizzuto et al. 1998). 
Initially, the virion binds to the host cell receptor (T cells) by non-covelant interaction 
between the virion surface envelope glycoprotein, gp120, and the protein receptor, CD4. 
Once CD4 binds the virion envelope glycoprotein gp120, the later undergoes a change in 
its conformation that enables it to engage the co-receptor CCR5. This step then triggers 
fusion of the virus with the cell membrane (Wilen et al. 2012). Finally, gp120 dissociates 
from the membrane-anchored gp41. Then, gp41 refolds in a series of sequential steps that 
leads to a closer contact of the viral envelop (Env) with the cell membrane (Liu, et al. 
2008).  The viral core is then delivered into the host cell. (Chen, et al. 2005) 
The primary and tertiary structure and of both the virion envelope glycoprotein, 
gp120, and the cell receptor, CD4, play an important role in the ultimate formation of the 
envelope complex. (Wu,et al 1996) The virion envelope glycoprotein structure is showed 
in Figure 1.1. The gp120 , synthesized in the endoplasmic reticulum, consists of 25 β-
strands, 5α helices and 10 defined loop segments (Kwong et al. 1998). The gp120 is 
found as trimers on the surface of the viral membrane.(Liu, et al 2008) and it is folded 
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into two major domains: five highly conserved inner domains (C1-C5) and five hyper 
variable loops (V1-V5). The conserved domains are important for gp120 folding and 
binding of the co-receptor, CCR5 (Rizzuto et al. 1998), the variable domains are involved 
in immune evasion and conformational modifications. (Wilenet al.2012)  
The cellular receptor CD4 is an immunoglobin protein conformed of three 
regions: an extracellular region, a hydrophobic trans membrane domain, and a highly 
charged cytoplasmic domain containing 370, 26, and 38 amino acid residues respectively. 
(Capon et al. 1991) The extracellular region of CD4 contains four recognized 
immunoglobin (Ig)-like domains denoted D1,D2,D3 and D4. (Harrison et al. 1992). D1 
and D2, showed in Figure 1.2, are defined as the membrane distal two-domain fragment; 
meanwhile D3 and D4 are known as the membrane proximal two-domain fragment. In 
particular the D1 domain contains a specific binding site for the glycoprotein, gp120 (Wu 
et al. 1996)  
 
Figure 1.1: A ribbon drawing of the HIV-1 glyco protein 120 (gp120) 
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Figure 1.2: Ribbon diagram showing organization of the distal two domain fragment 
D1and D2 of the CD4 cellular receptor 
GP120 undergoes a change in its structural conformational after binding the 
protein receptor CD4. This complex is mediated by chemokine receptor CCR5. (Kwong, 
et al., 1998). The D1-D2 extracellular fragment of CD4 the receptor protein binds gp120 
in a depressed region formed at the interface of the outer domain with the inner domain 
and the bridging sheet of the gp120 (Figure 1.3). This region is surrounded by 
carbohydrate moieties and is partially occluded by the flexible loops V1 and V2. (Wilen. 
et al. 2012). The molecular interaction between CD4 and gp120 occurs by direct 
interatomic contacts between 22 CD4 amino acids residues and 26 gp120 amino acid 
residues which results in 219 van der Waals contacts and 12 hydrogen bonds. The most 
important interactions, Phe43 and Arg59 of CD4 make multiple contacts on residues 
Asp368, Glu370, and Trp427 of gp120. (Kwong, et al., 1998) These interactions induce 
the conformational modification of the conserved inner domain of gp120 promoting the 
independent moving of each domain  (Chen, et al. 2005) This modification is enhanced 
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by the flexibility of the D1-D2 domains of CD4 (Liu, et al 2008) The overall 
modification induced by these interactions causes:a 30° rotation of  the three strand 
antiparallel sheet , the formation of four-stranded bridging sheet , and the displacement of 
the four-turn α-helix away from the outer domain (Figure 1.4). (Chen, et al. 2005). As a 
result, the V3 loop region is released from the lateral edge of the glycoprotein 120 and 
oriented into the target cell (Liu, et al 2008). 
 
Figure 1.3: Un-ligated SIV gp120 core structure 
The complex formed during the interaction of gp120 and CD4 causes viral 
proteins to bind the chemokine co-receptor type 5 (CCR5) (Wilen et al. 2012). CCR5 is a 
trans membrane protein that contains 352 amino acids and has a molecular mass of 40.6 
kDa (Figure 1.5). The CCR5 has 3 external closed loops (ECL1, ECL2, ECL3) and 4 
internal closed loops (ICL1, ICL2, ICL3, ICL4). This chemokine receptor is expressed in 
T-lymphocytes with memory/effector phenotype, monocytes, macrophage, and immature 
dentritic cells. The amino acids aspartic acid and glutamic acid at the N-terminal of 
CCR5 confer acidic properties to CCR5 (Oppermann et al. 2004). Additional negative 
charges are conferred by sulfation of tyrosine residues at positions 3,10,14 and 15(Farzan 
et al. 1999) and improves the capability of CCR5 to interact with the envelope 
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glycoprotein, gp120. (Oppermann et al. 2004). Furthermore, tyrosine-sulfated residues in 
the N-terminal of CCR5 bind the V3 loop and the bridging sheet. In order to bind the 
sulfated tyrosine residue at the CCR5 receptor, the V3 loop is modified into a rigid β-
hairpin by additional conformational changes of the gp120 (Huang et al. 2007) caused by 
formation of numerous hydrogen bonds in the V3 loop. (Wilen et al. 2012) 
 
 
Figure 1.4: Conformational changes in the gp120 during binding of the protein receptor 
CD4. 
7 
 
 
Figure 1.5: Two dimensional topology of the Human CCR5 sequence. 
The viral genomic load is delivered to the cell by a generalized “cast-and-fold” 
fusion mechanism induced by a conformational change of the glycoprotein, gp41. 
(Melikyan et al, 2008). The core of gp41 , showed in Figure 1.6, is composed of a trimer 
of two interacting peptides.  Structurally, the gp41 is formed by six helical bundles. The 
internal N-terminal helical regions (HR-N) is formed of three parallel coiled-coiled 
trimer, meanwhile the C-terminal helical regions (HR-C) are packed in an oblique, 
antiparallel manner to form highly conserved, hydrophobic grooves in the surface of this 
trimer. (Chan et al, 1997).The result is a highly stable six-helix bundle (6HB) (Wilen et 
al, 2012). However, a delivery pore is initially catalyzed by pre-bundle and energetically 
unstable structures. These occurs in the HR1 and HR2 regions and are critical for fusion. 
(Melijyan et al. 2008) The early pre-bundle is characterized by the maximization of the 
distance between HR-N and HR-C. Meanwhile, the late pre-bundle describe the 
formation of the nascent fusion pore (Wilen et al. 2012). Finally, the 6HB dilates the 
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delivery pore to a size that permits the transfer of the viral load (Figure 1.6). (Melikyan, 
et al 2008) 
 
Figure 1.6: HR-C and HR-N of the gp41 
Inhibition of HIV entry 
Inhibition of the HIV entry mechanism can occur at any of the three major steps 
of the interaction between the viral envelope proteins and cell membrane protein 
receptors. The inhibition of the attachment and binding of receptor CD4, binding of co-
receptor CCR5, and membrane fusion are the principal focus for the development of 
drugs that can limit the infectivity of the virus. (Wilen et al. 2012).The discovery of 
mechanistically novel HIV-1 inhibitors has resulted in the development of new drugs like 
Enfuvirtide (Meanwell et al. 2003) and Maraviroc (Lieberman-Blum et al. 2008) that 
interfere with the function of gp41 and CCR5 interaction respectively. Although these 
drugs are relative important to prevent the HIV entry, the study of the inhibition of the 
three other stages of entry mechanism is also to understand the drug activity and design 
(Wiley et al. 2012). 
Several anionic polymers have been shown to inhibit the attachment and binding 
of gp120 with CD4. These anionic organic compounds that include various naphthalene 
disulfonates disrupt the interaction of the gp120–CD4 that suppresses the efficiency of 
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HIV-1 infection (Rusconi et al. 1996). These polymers are directed to prevent the 
electrostatic interaction between the positively charged viral envelope and the negatively 
charged cell surface. However, these polymers have not in vivo efficacy when used as 
vaginal microbicide (Wiley et al. 2012). In contrast, other drugs which target the CD4 
binding site in gp120 have shown promising activity to prevent further interaction 
between the viral envelope and the CD4 receptor. For example, BMS-378806 is a small 
molecule that binds gp120 and inhibits the interaction of the envelope protein and the 
cellular receptor (Lin et al. 2003). Another small molecule drug, BMS-488043 directly 
inhibits the conformational changes of the CD4 and CCR5 binding sites in the gp120. 
(Ho et al. 2006).  
The discovery of resistance to HIV-1 infection in individuals with mutation in 
CCR5 demonstrates that this co-receptor is essential element of virus – cell membrane 
fusion. The mutant allele the CCR-5, Δccr-5, prevents membrane fusion (Libert et al, 
1998). A 32-bp deletion within the coding sequence in the region that corresponds to the 
second extracellular loop has been identified as the mutation region (Samson et al. 1996). 
Hence, the development of new drugs is directed towards the inhibition of the co-receptor 
CCR5. For example, Maraviroc, has been approved for human use in 2007 by the FDA 
as well as other CCR5 antagonists that bind a hydrophobic pocket in the trans-membrane 
domain of the CCR5. These antagonists bind not at the region in which V3-gp120 
interacts with the co-receptor, but likely in a way that induces allosteric modification of 
the second extracellular loop and consequently prevents the cellular fusion (Baba et al. 
1999). Interestingly, the chemokine receptor CCR-5 interacts with some natural native 
secreted proteins such as macrophage-inflammatory-protein (MIP)-1α, MIP-1β and 
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RANTES to block the HIV-1 infection. However, nonpeptide CCR5 antagonists have 
been also discovered. Thus, there is a need to develop other CCR5 antagonists for 
inhibition of the CCR5 interaction (Wilen et al. 2012). 
Cell fusion inhibitors are directed to bind the viral envelope glycoprotein gp41 
and prevent the formation of the fusion pore. For example, Enfuvirtide, a 36 amino acid 
peptide, binds directly to the HR-N region and prevents the formation of the hair pin 
structure that enhances the formation of the fusion pore. (Moyle et al. 2003). However, 
this drug has demonstrated to be ineffective against some strains that present mutation in 
the HR-N region of the virus (Wiley et al. 2012). Another set of drugs that inhibit the 
functionality of the glycoprotein, gp41, are D-peptides. These D-peptides target the 
hydrophobic pocket of the gp41 as Enfuvirtide prevents the formation of the hair pin 
structure of gp41 (Welch et al.2007). 
RANTES Expression, regulation, and HIV entry inhibition  
Regulated-on-Activation-Normal-T-cells-Expressed-and-Secreted (RANTES) is a 
pro inflammatory human native protein that belongs to the chemokine family proteins 
and has high affinity to CCR5 receptors in T cells. RANTES is expressed in cytotoxic 
CD8+ phenotype and the helper CD4+ T cells as a response to inflammatory viral 
infection (Song et al. 2000). Once cells have been activated by antigen binding, RANTES 
mRNA is induced after three to five days of activation. This late expression is 
characterized by a change in the expression patterns of T cells needed for T lymphocytes 
cells to a mature. The human RANTES gene has been located on chromosome 17 and 
composed of three exons and two introns (Figure 1.7) (Nelson, et al 1993). In addition, 
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the RANTES Factor of Late Activated T Lymphocytes-1 (RFLAT-1) works as an 
activator in the RANTES promoter cis-acting binding and regulates its expression. The 
RFLAT-1 belongs to the family of zinc finger transcription factors (Song et al. 1999). 
 
Figure 1.7: Human RANTES introns and exons 
RANTES is a member of the CC chemokine family that forms a stable dimer at 
neutral pH and has the tendency to aggregate at pH 4.0. Each monomer contains a C-
terminal α-helix packed against a three-stranded antiparallel β-sheet and two short N-
terminals β-strand (Figure 1.8). The N-terminal regions are considered important to dimer 
formation (Skelton et al. 1995). RANTES has four cysteine residues contained in a 68 
amino acids polypeptide. Two adjacent cysteine residues form the characteristic CC 
sequence of chemokine family members (Figure 1.9) (Nishiyama et al. 2002).  
 
Figure 1.8:  dimer structure of RANTES 
 
Figure 1.9: Amino acid sequence of human RANTES 
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RANTES function in the recruitment of T cells to the inflamed tissue and is a 
powerful chemoattractant for many other cells as monocytes, NK cells, memory T cells, 
eosinophils, and dendritic cells (Crawford et al, 2011). The high affinity between CCR5 
receptor and RANTES make inhibition of the infection by HIV-1. RANTES, MIP-1α and 
MIP-1β, are considered a suppressive factors during HIV-1 infection (Cocchi et al 1995). 
It is known that aggregation of RANTES is important for chemotaxis activity even 
though the physiological dimeric structure of RANTES has not been well defined (Appay 
et al. 2000). RANTES possesses two distinct regions that have been identified as the 
regions that interact with the chemokine receptor, CCR5. The N-terminal and the N-loop 
region are the regions that have demonstrated interaction with the HIV’s co-receptor, 
CCR5 (Nardese et al. 2001). The N-loop residues Phe 12, Ile 15, and Tyr 27 – Tyr 29, 
(Figure 1.10) have been identified as contributors to the formation of large hydrophobic, 
solvent exposed patches that provide a high docking interaction with the trans-membrane 
protein, CCR5 (Nardese et al, 2001).   
 
Figure 1.10: Dimeric structure of RANTES and critical amino acids residues 
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RANTES chemokine analogues  
New HIV-1 preventive and protective drugs used as microbicides are being 
developed on mucosal surfaces to decrease the sexual transmission of the HIV. In that 
context, RANTES is a natural inhibitor to prevent and block the entry mechanism of the 
tropic HIV-1. Even though there is not universal agreement about the entry mechanism in 
mucosal surface, the HIV-1 co-receptor CCR5 is known to be involved in the entry 
process. Thus, the focus of research and development has been directed to the discovery 
of effective microbicides that possess analogous function as the native RANTES  
(Lederman et al, 2004). 
Aminooxypentane (AOP)-RANTES is one of the first analogue antagonists of 
CCR5 developed to protect macrophage and lymphocytes from infection. AOP-RANTES 
was generated by the addition of an aldehyde-like group at the amino terminus of native 
RANTES and then reacting with aminooxypentane. This peptide offers strong inhibition 
of the co-receptor CCR5 and does not induce chemotaxis (Simmons et al, 1997). 
Another RANTES analog, Nα-(n-nonanoyl)-des-Ser1-[L-thioproline2,L-α-
cyclohexyl-glycine3]RANTES (PSC-RANTES) introduce a nonanoyl group, thioproline 
and cyclohexylglycine in the position that correspond to the first three amino acids 
(Ser,Pro,Tyr) of the native RANTES. Initially tested in rhesus macaques, PSC-RANTES 
has resulted in the  depletion of free CCR5 co-receptors (Lederman et al, 2004) This 
discovery has led to the likelihood that PSC-RANTES involves long-term intracellular 
sequestration of CCR5 and also a strong CCR5 signaling activity (Hubert et al, 2008). 
14 
 
Further investigation of the PSC-RANTES has demonstrated to be fifty times more 
potent than AOP-RANTES (Hartley et al, 2004). 
PSC-RANTES is a potentially microbicide that raise the potential for a more 
affordable and environmentally stable compounds. Although, PSC-RANTES has 
demonstrated both high signaling activity and co-receptor sequestration, it has the 
tendency to produce inflammation which enhances the chance for HIV-infection. Two 
analogs called 5P12-RANTES and 6P4-RANTES have been identified using PSC-
RANTES as the platform molecule (Hubert et al, 2008).  5P12-RANTES features high 
anti-HIV activity but no CCR5 signaling and no CCR5 sequestration. However, 6P4-
RANTES offers high anti-HIV activity, high CCR5 signaling activity and high CCR5 
sequestration. Both analogues offer high resistance to hydrolysis at temperature in the 
range of 40 to 55°C. In addition, both are very stable at acidic vaginal pH (4.0) and have 
resistance to degradation during incubation with human cervicovaginal lavage and human 
semen (Cerini et al, 2008). However, the principal characteristic of both analogues is the 
primary structure that contains naturally occurring amino acids. This makes them suitable 
for large scale recombinant production by using microorganism such as yeast (Hubert et 
al, 2008). 
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CHAPTER II 
CELL LINE CONSTRUCTION AND FERMENTATION DEVELOPMENT 
Abstract  
Pichia pastoris is a well know microorganism that has the ability to express extra 
and intracellular recombinant proteins.  Pichia pastoris has a large amount of genotype 
strains that are derived from the wild-type strain Y-11430. The X-33 is also a wild-type 
strain that have the capability to accept recombinant gene. A great variety of expression 
vectors for P. pastoris enables the facile development of multiple clonal linages 
containing the recombinant gene. Using a yeast shuttle vector one can select clones that 
can express the protein of interest from those who are not capable of expression. The 
presence of the alcohol oxidase enzyme (AOX) in the genomic information of the yeast 
Pichia pastoris is particularly beneficial for selection and induction of cells that produce 
the protein of interest. The AOX enzyme allows the usage of methanol as the sole carbon 
source for the production of biomass and energy metabolism. The expression of protein 
and posterior translocation depends in the particular features of some shuttle vectors. For 
example, the pPICZαA vector has the ability to secrete the protein of interest out of the 
cell into the fermentation broth. Secretion is achieved by the addition of the α-leading 
factor transcriptional unit. The leading factor is removed in the Golgi apparatus by 
enzymatic action of the KEX2 protease that allows the secretion of the protein of interest. 
In this research, The X-33 wild type is used as host microorganism for the vector 
pPICZαA–5P12-Rantes.  
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The fermentation development focused in both the determination of the maximum 
growth rate and the establishment of a relation between the methanol growth rate and the 
methanol feed rate. The rate of growth was determined to be 0.0807 h-1 using methanol as 
sole carbon source. The equation νMeOH = 0.7573 (µMeOH) + 0.0024 relates the methanol 
feed rate with the methanol growth rate. 
Introduction 
Pichia pastoris as a suitable system for heterologous protein expression  
Pichia pastoris, recently reassigned to its genus Komagataella pastoris (P. 
pastoris) (Kurtzman et al, 2009), has been largely used for recombinant protein 
production. (Cregg et al, 2009). The P. pastoris system has the potential to express 
correctly folded proteins, grow at large cell density, use methanol as sole carbon source, 
and produce large amounts of protein using the alcohol oxidase (AOX) promoter that 
drives the gene expression of the desired protein (Daly et al, 2005). 
The formation of haploids during P. pastoris life cycle offers advantages for the 
isolation and phenotype characterization of mutants. Mating occurs on nitrogen 
limitations and diploid cells are formed. P. pastoris is by definition homothallic and after 
mating the resulting diploid products can be maintained in the state by shifting to a 
standard growth medium.  In this context, P. pastoris life cycle enables genetic 
manipulation due to its stability in the haploid state (Cregg et al, 1998). 
P. pastoris offer a great variety of strains that can facilitate and enhance the 
production of recombinant proteins. For example, the wild type strain, X-33, is a positive 
methanol utilization strain. The strain GS115 is defective in the histidine dehydrogenase 
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gene (his4), and its use allows transformants to be selected based on the ability to grow in 
non-histidine containing media. The strain KM71 is a strain which chromosomal Alcohol 
Oxidase 1 (AOX1) has been deleted. KM71 uses a weaker promoter alcohol oxidase 2 
(AOX2) that metabolize methanol in a lower rate than AOX1. Some other strains have a 
lower grade of vacuolar proteases that can degrade protein especially during high density 
cell fermentation. SMD1165 and SMD1163 are defective in vacuolar proteases and may 
help to reduce protein degradation (Higgins et al, 1998. Daly et al, 2005).  
Expression vectors for P. pastoris have both common and specialized features. 
All vectors contain an expression cassette which is composed of a promoter sequence 
(commonly AOX1 promoter), multiple cloning sites for gene insertion and a 
transcriptional termination sequence that allows efficient polyadenylation (Li et al,2007). 
However, the most important feature is that all E. coli / P. pastoris shuttle vectors contain 
an origin of replication for plasmid maintenance. These vectors also have functional 
markers that make them usable for marker selection in both organisms (Cereghino et al, 
2007). Specialized vectors are selected according to the expression requirements. For 
example, there are vectors that favor intracellular expression, some that favor 
extracellular secretion, some that offer different selectable markers or antibiotic 
resistance, and some that use promoters other than AOX1 (Higgins, Busser et al, 1998, 
Cereghino et al 2007). In this context, the vector pPICZαA induces extracellular protein 
secretion using the alpha mating factor (α-MF) secretion signal. This vector uses zeocin 
as antibiotic marker and allows plasmid integration to the AOX1 locus. These 
characteristics make this vector an optimal option when extracellular expression is 
required (Siren et al, 2006).  
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The glyceraldehyde 3-phosphate dehydrogenase (GAP) and AOX1 promoter are 
the more useful promoters during heterologous protein expression. The GAP promoter 
allows strong constitutive expression using either glucose or glycerol. However, the GAP 
promoter activity in cells grown in glycerol is two-thirds of the level observed for glucose 
(Cereghino et al, 2000). However, GAP promoter induce the production of acetate and 
ethanol than may be harmful to the protein of interest (Li et al, 2007).  
The AOX1 promoter is used to drive the expression of recombinant proteins to 
high levels using methanol as sole carbon source (Daly et al, 2005). When AOX1 enzyme 
represents the 30% of the total protein content, AOX1 production may be induced by 
switching carbon source from glycerol to methanol. However, the importance of using 
AOX1 as a drive promoter resides in its functionality to metabolize large amounts of 
methanol to produce for both production of cell material and metabolism (Bollok et al, 
2009). 
Alcohol Oxidase (AOX) is the first enzyme that acts on the metabolic pathway of 
methanol. AOX is an oligomericflavoprotein that contains the flavin adenine dinucleotide 
(FAD) and the modified flavin adenine dinucleotide (mFAD). These flavoproteins are 
non-covalently attached to AOX to accomplish electron transfer (Bystrykh et al, 1991. 
Daly et al, 2005). P. pastoris has two genes that code for the alcohol oxidase enzyme: 
alcohol oxidase 1 (AOX1) and the alcohol oxidase 2 (AOX2). The AOX1 is responsible 
for at least 90% of the AOX activity, and AOX2 accounts for the rest (Pla et al, 2006). 
AOX is sequestered within the peroxisome along with catalase. AOX oxidizes methanol 
to formaldehyde and hydrogen peroxide that it is degraded by catalase (Figure 2.1). A 
portion of the produced formaldehyde leaves the peroxisome and is further oxidized to 
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formate and carbon dioxide by cytoplasmic dehydrogenases. These last reactions are the 
source of energy for cells growing on methanol. (Cereghino et al, 2000) 
 
Figure 2.1. The methanol pathway in P. pastoris. 1 alcohol oxidase; 2 catalase; 3 
formaldehyde dehydrogenase; 4 formate dehydrogenase; 5 dihydroxyacetone synthase; 6 
dihydroxyacetone kinase; 7 fructose 1,6-biophosphate aldolase; 8 fructose 1,6-
biphosphatase. 
P. pastoris phenotypes are selected on the capacity to metabolize methanol: 
methanol utilization positive (Mut+), Methanol utilization slow (Muts) and Methanol 
utilization negative (Mut-). These phenotypes are the possible outcomes that can result 
after homologous recombination in the AOX1 promoter (Daly et al, 2005). 
Transformants with Mut+ can synthesize large amounts of methanol due to the expression 
of AOX1. Muts transformants can processes low quantities of methanol mainly caused by 
the deletion of the AOX1 and expression of the weaker enzyme AOX2. Mut- phenotypes 
contain neither AOX1 nor AOX2 in its genome (Pla et al, 2006).   
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P. pastoris allows high levels of recombinant protein expression due to its ability 
to reproduce and maintain high-cell densities during fermentation (Inan, et al 1999). 
Fermentation process can be subdivided in four operative sections. First, the batch phase 
in which P. pastoris grows freely using a salt medium with a non-fermentable carbon 
source like glycerol. Second, the fed-batch phase is mainly characterized for the growth 
under glycerol grow-limiting rate. Under this phase sub-products produced during batch 
phase like ethanol are used by the yeast, making them ready for the use of methanol 
(Zhang et al, 2000). Third, the transition phase characterized for a first injection of 
methanol and a constant reduction of the glycerol feed rate for three hours. This phase is 
of particular interesting because it defines the time zero for induction (Zhang, et al 2000). 
Finally, the methanol induction phase in which the carbon source is fed at growth 
limiting rate to avoid any prejudicial accumulation that may affect the cell. The induction 
phase activates the expression of the protein of interest (Cereghino et al, 2000).   
Material and Methods 
DNA Sequence construction, transformation and multiple inserts screening 
5P12-Rantes DNA sequence was obtained from The Mintaka Medical Research 
Foundation trough the Biological Process Development Facility (BPDF) at University of 
Nebraska – Lincoln (UNL). The DNA sequence was synthesized by Gene Script and 
inserted in the pUC57 vector. The pUC57 containing the 5P12-Rantes gene was 
subcloned into E. coli DH5α strain. The E. coli DH5α–pUC57–5P12-Rantes strain was 
plated in Lb agar plate containing 100 mg/L ampicillin. Then, the pUC57–5P12-Rantes 
vector was extracted and purified as instructed in the DNA qiagen Miniprep kit. The 
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purified vector was digested with restriction enzymes Not I and Xho I. The digested 
solution is separated using agar gel. The DNA sequence that corresponds to the 5P12-
Rantes was extracted from the gel and then purified. The purified 5P12-Rantes sequence 
is inserted into a previously digested pPICZαA vector and sub cloned into E. coli DH10B 
strain. Purified DNA sequence was shipped for sequence confirmation. Finally, the E. 
coli DH10B strain containing the pPICZαA–5P12-Rantes sequence was plated in Lb 
agarose gel with 5µg/L zeocin. 10 mL Lb broth is inoculated with 1µg of a well round 
shape form colony. The Lb broth is incubated at 37°C and 200 rpm for 10 hours. 1.5 ml 
of the resulting broth was treated as indicated in the Qiagen Miniprep Kit and later 
digested with PmeI enzyme for DNA linearization.  
P. pastoris wild type X-33 is used as the hosting microorganism. Fresh competent 
cells are used for electroporation (Wu, et al 2004). Finally, P. pastoris transformation is 
completed by electroporation as indicated in section of transformation in the Pichia 
pastoris protocols (1998). The solution containing the transformants is plated in YSDS 
agar plates containing 100, 200, 500, 1000 and 1500 µg/mL zeocin. Colonies started to 
appear after 3 days of incubation at 30°C. 
Table 2.1: X-33 amplification in YSDS/zeocin agar plates 
YSDS/ Zeocin concentration Colonies 
100 µg/mL 25 
200 µg/mL 16 
500 µg/mL 6 
1000 µg/mL 2 
1500 µg/mL 0 
 
28 
 
Mut+ phenotype selection  
Phenotype selection of the transformants is performed to discriminate strains with 
AOX activity from those whose AOX sequence has been deleted. A number is assigned 
to the each colony that grows in the YSDS plates. Each colony is transferred from the 
YSDS plate to Minimal Dextrose (MD) agar plate and the same colony is used to 
inoculate Minimal Methanol (MM) agar plates. Plates were incubated at 30°C and 
checked for colony formation every 24 hours. 3 colonies grew after 35 hours of 
inoculation. The colonies with the assigned number 8, 30 and 32 were chosen for further 
processing. This selection was based in the high zeocin resistance assuming that higher 
resistance is an indication of multiple sequence insert. The selected clones are assumed to 
have a better capability to metabolize methanol. All colonies grew after 48 hours of 
incubation however this indicates a slow tendency to metabolize methanol.  
Table 2.2: Clones with high zeocin resistance 
Colony Number Zeocin Resistance 
8 500 µg/mL 
30 200 µg/mL 
32 200 µg/mL 
 
Selection of the clone is completed by running 3 fermentation batches using Basal 
Salts Medium (BSM). Each batch ran at 1g/L methanol saturation in which clone number 
8 showed to have a better capability to metabolize methanol as carbon source. Even 
though, clones number 30 and 32 have zeocin resistance both have demonstrated 
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methanol accumulation during fermentation reaching about 700 and 1300 ppm of 
methanol accumulated in the vessel during induction phase.  
Fermentation Development 
Fermentations were developed using 3 5-liter Bioflo III fermentor interfaced with 
the computer base software AFS – Biocommand32 (New Brunswick Scientific Co. 
Edison, GA). The outlet gas was diverted into two lines. The first line was directed to 
monitor the methanol concentration in the fermentation broth using a MC-168 methanol 
concentration monitor and controller (PTI instruments, Inc., Kathleen, GA). The second 
line was derived to a process mass spectrometer for on-line fermentation gas analysis 
(PrimaδB VGgas Thermo-Fisher Scientific) The AFS-Biocommand32 interface was used 
to monitor and control a peristaltic pump used for methanol feed (Model 101U/R, 
Watson-Marlon Ltd. England), scale (Model PG 12001-S, Mettler Todelo, Switzerland), 
and the methanol concentration monitor and control.  
The main objective of the fermentation development process, using P. pastoris as 
host, is to obtain a high protein production level with a low methanol accumulation and 
high cell density. Fermentation process may be subdivided in four sections: Batch phase, 
glycerol fed batch phase, transition phase and induction phase. 
The fermentors were inoculated with 100 ml of BMGY incubated for about 19 
hours with 1 mL of stock culture at 30°C and 250 rpm shaking rate. Once the optical 
density at 600 nm (OD600) reached a value between 8 and 10 the shake flask was stopped 
and aseptically 100 mL was transferred to each fermentor.  
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Each fermentation batch used 2L of BSM. Before inoculation, 8.7 ml of PTM1 
salts and 2 mL of 5%v/v antifoam were injected directly to the vessel. The fermentation 
medium pH was adjusted to 5 with 20–30% ammonium hydroxide. The temperature was 
set up to 30°C and dissolved oxygen to 40%. Agitation was initially at 400 revolutions 
per minute (rpm) and set up in cascade response so the agitation will increase to maintain 
dissolved oxygen (DO) at 40%. These conditions are maintained until all the initial 
glycerol contained in BSM is consumed. 
The fermentation batch phase has the objective to generate biomass prior to the 
production of protein. Glycerol, included in BSM, is used as the sole carbon source in the 
phase and the microorganism grows at non-limiting carbon supply. The table 2.3 provides 
information about the data extracted from this phase. Since the glycerol concentration in 
BMS is the same for all runs the results showed have little variability. 
Table 2.3: Data from fermentation batch phase for a total of 20 experiments 
Variable Range 
Batch phase specific growth rate 0.1766 - 0.1769 h-1 
Cell mass produced  98 – 100 g wet cells/L  
Glycerol yield  2.45 – 2.5 g wet cells/g glycerol  
 
The depletion of glycerol in BSM is characterized by a rapid increment in the DO 
value that is also known as DO spike which indicates the culmination of the batch phase 
(Inan et al 1999). During the glycerol fed-batch phase, a solution of 63% weight/volume 
(w/v) glycerol with 12 mL/L PTM1 salts is fed to the fermentation broth at 20 
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gr/Liter/hour feed rate (Zhang, 2000). During this phase all the sub-products (ethanol, 
acetate) produced in the batch phase are used for cell maintenance and growth (Zhang, et 
al2000). Glycerol fed-batch phase is completed after 1 hour of glycerol fed to obtain 
about 120 to 125 g wet cell/L.  
Transition phase starts after 1 hour of glycerol feed. 1 g MeOH/L (1.26 mL/L) 
broth is injected into the fermentor and marks the time zero for induction. The glycerol 
feed rate is decreased from 20 g/L/h to 0 g/L/h over 3 hours. The mass spectrometer 
shows an increase in the methanol concentration in the fermentor after the first injection. 
The concentration of methanol decreases over time indicating the capability of cells to 
metabolize methanol. The transition phase is particularly important due to the gentle 
switch from glycerol to methanol will improve the cell ability to metabolize methanol 
(Zhang, et al 2000).   
Methanol fed-batch phase starts once the methanol concentration measured by the 
mass spectrometer has decreased about 50 ppm.  Methanol feed profile is developed to 
estimate both maximum growth rate and optimal process conditions.    
Maximum growth rate development 
The maximum growth rate indicates the rate at which P. pastoris grows in a non-
limiting carbon source environment. To obtain the maximum growth rate (µmax), a 
fermentor was set up with 2L of BSM with 8.7 mL of PTM1 salts at pH 5.0. After DO 
spike, glycerol is fed at 40 g/h over 1 hour. 1 g MeOH/L was injected in the fermentor 
and the concentration was determined by the methanol sensor. The processed outcome 
was monitored with the AFS-Biocommand32 interface. 1g MeOH/L saturation is 
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indicated by a constant value in the Biocommand trend view. Once the methanol 
concentration decrease, a second injection is performed and methanol feed starts once the 
constant saturation value is reached. Methanol pump feed rate is controlled by the AFS-
Biocommand32 interface to maintain 1g MeOH/L saturation value in the fermentor. The 
table 2.4 shows the values to determine the specific growth rate.  
Table 2.4: Fermentation values for maximum growth rate determination 
Induction time Wet Cell Weight Fermentor Volume Biomass 
5.60 135.4 2.05 277.57 
11.01 190.2 2.23 424.146 
12.98 215.3 2.32 449.496 
14.00 232.3 2.37 550.551 
 
 
Figure 2.2 : Exponential regression to calculate maximum growth rate 
 
The exponential regression shows that the specific growth rate has a value of 0.0807 h-1. 
y = 175.98e0.0807x 
R² = 0.9991 
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Methanol Feed profile development 
Methanol feed profile is developed to obtain an equation that will determine the 
relationship between the methanol consumption rate (νMeOH) and the growth rate during 
the methanol fed-batch phase (µMeOH). The growth rate will be limited by the amount of 
methanol fed during the methanol fed-batch phase. Four runs at different growth rates are 
performed. An equation proposed for methanol consumption rate (Sinha et al, 2003) is 
used as reference to determine the real relationship for this specific clone. 
Table 2.5: Values for methanol consumption rate determination. 
Fermentation Proposed µ*MeOH Real µMeOH Real νMeOH 
1 0.01 0.009 0.0099 
2 0.025 0.0259 0.0225 
3 0.04 0.0399 0.0302 
4 0.06 0.0645 0.0524 
 
The relationship between µMeOH and νMeOH is determined by linear regression with 
the calculated values (Zhang, et al 2000). The final equation is: 
νMeOH = 0.7573 (µMeOH) + 0.0024 (eq. 2.1) 
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Results and Discussion  
The development of P. pastoris growth rate and methanol consumption rate is 
important to the precise control of the amount of methanol fed during the methanol fed-
batch phase. This information will allow to manage the methanol feed pump that 
ultimately is controlled by the AFS-Biocomand32 interface in which this data is entered. 
Determination of the maximum growth rate for this specific clone is useful 
information towards the development of the fermentation process. The calculated value 
of 0.0807 h-1 was obtained at 1g/L methanol saturation in the fermentor vessel. 
Concentration higher than 3.75 g/L methanol saturation will have inhibitory effects on 
the specific growth rate (Zhang, et al 2000). 
The equation proposed by Sihna et al 2000, was adjusted to the actual values that 
correspond to this specific clone. For all four fermentations, methanol was fed in a quasi-
steady state condition at different exponential growth rates. This fermentation were 
performed below the inhibitory growth levels (Sihna, et al 2000). The actual equation 
(νMeOH = 0.7573 (µMeOH) + 0.0024) will be used in the experimental design for the 
exponential growth and exponential methanol feed rate. 
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CHAPTER III 
RESPONSE SURFACE METHODOLOGY AND CENTRAL COMPOSITE 
DESIGN 
ABSTRACT 
Fermentation process development focuses upon the optimization of expression of 
a target molecule. The central composite design and the response surface methodology is 
a mathematical and statistical tool for evaluating the responses necessary to optimize a 
fermentation process (Dey et al 2001, Hao et al 2006). P. pastoris is frequently used for 
the production of recombinant heterologous proteins (Inan, et al 1999). However, there 
are many variables that may affect cell’s productivity. These variables may include pH, 
temperature, Dissolve Oxygen, Agitation speed, medium composition, methanol growth 
rate and methanol feed rate (Inan et al 1999). This research is focused in the evaluation of 
the effect of temperature, pH and Methanol growth rate are evaluated in their effect on 
the total protein secretion, active protein secreted and Specific yield in the yeast P. 
pastoris. 
The central composite design (CCD) is an experimental design used to allocate 
the operation variables into a range of evaluation. Temperature, pH and methanol growth 
rate are evaluated in a range defined by the CCD.  
The response surface methodology (RSM) provides the statistical elements 
necessary for the evaluation of Temperature, pH and methanol growth rate. The RSM 
focused in the construction of geometrical models that can predict the behavior of the 
factors in the area of evaluation. In addition, the RSM enables the independent evaluation 
of each factor and their interaction within the proposed model. 
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INTRODUCTION 
Response surface methodology (RSM) is a collection of mathematical and 
statistical methods to evaluate relationships between a group of quantitative independent 
variables and one or more responses. The RSM enables to evaluate operation variables 
that may or may not have significant effect in the main response (Myers 1976, Parampalli 
et al 2007, Inan et al 1999). The optimization of fermentation process is an important step 
in the development of feasible processes (Ghosalkar et al 2008). The fermentation 
process optimization implies the evaluation of medium composition, glycerol feed rate, 
methanol feed rate, temperature, pH, dissolve oxygen, air/oxygen flow rate and agitation 
speed (Inan, et al 1999). In this study, temperature, pH and methanol growth rate are 
evaluated to determine their effect in the total amount of 5P12-Rantes produced, the 
active 5P12-Rantes and the specific yield.  
The central composite design, CCD, is used to build a second order experimental 
model (Myers, 1976). CCD is composed of a factorial design, a set of central points, and 
axial points equidistant to the center point.   
The factorial design component of CCD is of the class 2k factorial where k 
represents the number of relevant factors or variables. Each of the variables is taken at 
two levels meaning that each variable has a low and high numeric value. A coded 
numeric value of -1 and +1 is assigned to represent the variable’s low and high values. 
The geometric representation of a factorial is a cube in which each corner represents an 
interaction of the factors. In this perspective, 8 interactions are to be evaluated when 3 
processing variables are selected to determine their significance in the final response 
(Myers, 1976). 
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The axial component of CCD refers to the points that are equidistant from the 
center of the cube formed for the factorial design. A spherical design is obtained in the 
reason that there is an equal variance from the center to all the points in the sphere. In 
consequence, there is a positive axial value (+α) and a negative axial value (-α). The axial 
points add two more levels in each variable. The α value is calculated from the equation 
α = (ni)1/4. Where, ni represent the number of interactions obtained from the 
factorial design. Thus, for 8 interactions α = 1.682 (Myers, 1976).  
The central point component in the CCD is the average of the high and low values 
determined in the factorial design. The central point or zero point may be defined as the 
region where the optimal conditions are supposedly met. The addition of the central point 
in the design increases the level’s design in one unit to a total of 5 levels for each 
variable.  
 
Figure 3.1.  Layout of the Central Composite Design (CDD) for 3 variables at 5 levels 
The RMS allows the introduction of blocks that facilitate the accomplishment of 
experiments. Blocking is justified based on the physical and time limitations to run 
experiments. However, blocking may have some effects over the final response. If the 
estimations of the independent and interaction effects of the selected variables are not 
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affected by blocking, the inclusion of blocks in the experimental design is justified 
(Myers, 1976). 
The selection of variables for the analysis using RSM is completed in order to 
determine which factor may or may not have an important effect in the final response. 
Basic information about the protein sequence, pH stability, post transformational 
modifications will provide a better understanding of possible factors that can affect the 
protein production during fermentation.   
 
GROWTH CONDITIONS 
Methanol growth rate  
The methanol growth rate is determined during the induction phase. The amount 
of methanol fed during this phase is calculated using equation 2.1. The methanol feed rate 
is established by values determined in the CCD. The methanol feed rate determines how 
fast the microorganism grow using this carbon source. However, there is an important 
link between the methanol feed rate and the amount of protein produced in the reactor 
vessel during the induction phase (Zhang, et al 2000). A lower methanol feed rate implies 
a slow growth rate and a slow protein production that could or could not be beneficial for 
the overall production. In other hand, a high methanol feed rate results in a rapid grow of 
the microorganism and an accelerated protein production that may be affected by the 
elevated methanol feed rate. (Sinha, et al 2003). Nevertheless high cell density is reached 
in the least amount of time and the accumulation of methanol in the fermentation vessel 
could be detrimental for the microorganism. (Sihna, et al 2003, Zhang et al 2000). 
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Temperature  
Pichia pastoris generally uses temperature of 30°C (Wegner, US Patent 1983). 
However, the cell productivity may be affected by the temperature at which protein 
secretion is induced. Positive effects in production of heterologous recombinant protein 
have been reported when lowering temperature (Dragosits, et al 2008). Proteins tend to 
have more stability and proteases activity is decreased when fermentation is carry out at 
low temperatures. Nevertheless, low temperature during induction phase decrease the 
activity of the AOX enzyme and the tendency of accumulate methanol may have negative 
effects in the protein production. Temperatures ranging from 24°C to 30°C during the 
induction phase are preferably selected in order to evaluate their effect in the responses 
(Inan, et al 1999).  
pH 
Pichia pastoris has the ability to grow in a broader range of pH values. 
Expression of recombinant proteins were investigated in pH values from 3 to 7. The 
protein stability and activity is the main response to evaluated at different pH values 
(Inan et al 1999, Zhang et al 2000, Slininger  et al 1990). The Acidity or alkalinity in 
which the process is run has an effect in both microorganism growth rate and protein 
production. 
5P12-RANTES PROPERTIES 
The 5P12-Rantes, an anti-HIV microbicide, has a molecular weight of 7.905 KDa 
and isoelectric point of 10.2. This protein was developed with the final intention to be 
used as a vaginal topical gel and prevent the spread of HIV infections disease. The acidic 
environment of the vagina (3.5 to 4.2) dictates the 5P2-Rantes stability and activity under 
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this condition (Gaertner, et al 2008). The amino acid sequence of 5P12-Rantes was 
established after an exhaustive investigation in which the inclusion of a motif Q-G-P-P at 
the N-terminus (Figure 3.2) reveals a remarkable anti-HIV activity over the other 
candidates. The next five amino acids residues affect both anti HIV-potency and the 
capacity for receptor interaction (Gaertner, et al 2008). The complete 5P12-Rantes amino 
acid sequence has a total of 69 amino acid residues distributed as follow: Q G P P L M A 
T Q S C C F A Y I A R P L P R A H I K E Y F Y T S G K C S N P A V V F V T R K N 
R Q V C A N P E K K W V R E Y I N S L E M S  
 
Figure 3.2: 5P12-Rantes sequence at the N terminal 
 
The stability and activity of the 5P12-Rantes is limited by the spontaneous 
formation of a Pyro-glutamic residue at the N-terminal of the amino acid sequence and 
the formation of two disulfides bonds between the cysteine residues. The formation of the 
pyroglutamic acid (pyro-Q) enhances the protein stability, hydrophobicity and anti HIV-
potency. In addition, the pyro-Q improves low intracellular sequestration and decrease 
the G protein-linked signaling activity (Gaertner, et al 2008). The N-terminal glutamine 
(Q) is converted into pyro-glutamic acid (pyro-Q) (Figure 3.3) (Dick, et al 2006). The 
two disulfide bonds occur between the cysteine residues at position 11 with 35 and 12 
with 51 to form a G shape structure. The human Rantes structure has an analogous shape 
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to the 5P12-Rantes (Figure 3.4) (Burke-Gaffney et al 2002). The pyro-Q formation is an 
important post translational modification with effects in the functionality of the protein 
5P12-Rantes. The formation of pyro-Q at the N-terminal protects the protein against 
proteolitic degradation (Kumar et al 2012). 
 
Figure 3.3: The conversion of glutamine to pyro-glutamic acid 
 
The 5P12-Rantes stability and activity delimit the pH and temperature ranges of 
operation. However, the formation of the pyro-Q at the N-terminal during fermentation 
has not been investigated (Dick, et al 2006). Pyro-Q formation is induced by the increase 
of temperature in a non-enzymatic reaction. (Kumar et al, 2012)  
 
Figure 3.4: Human Rantes G shape with 2 disulfide bonds. The chemotaxis effect 
depends of the formation of the G-shape. 
Transformation of the un-cyclized form to cyclized is achieved by heating up 
purified 512-Rantes solution at 60°C, pH 6.0 and 100mM potassium phosphate. Even 
though this purification step maximizes the conversion of un-cyclized 5P12-Rantes, the 
usage of chemicals and energy increase the cost of downstream processing.  
45 
 
MATERIAL AND METHODS 
Central composite design 
A second order design composed of 3 blocks. 3 factors at 5 levels CCD was used 
to investigate the effect of methanol growth rate, temperature and pH in the production of 
5P12-Rantes, 5P12-Rantes activity and specific yield. The CCD comprises a total of 20 
experiments: a full factorial design (8 experiments), 6 axial points, and 6 central points. 3 
blocks were used to subdivide the experiments in three groups. 4 factorial points with 2 
central points for the first two blocks and the third one comprise 6 axial points with 2 
central points. Each block represents a bioreactor and 2 central points are proposed to 
estimate the error for each bioreactor. 
 
Table 3.1: 3 factors at 5 levels estimated values 
Factor Axial (-α) Low (-1) Normal (0) High (+1) Axial (+α) 
Methanol growth rate (MeOHGR) h-1 0.010 0.016 0.025 0.0339 0.040 
Temperature (T) °C 24.06 25.25 27.00 28.75 29.94 
pH 1.98 2.50 3.25 4.00 4.51 
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Table 3.2: CCD matrix for 3 factor 5 level 3 blocks 
Block Coded Values Un coded values Lot Number 
MeOH (X1) Temp (X2) pH (X3) MeOH Temp pH 
1 -1 -1 -1 0.0161 25.25 2.50 MK-GR- 11 
1 +1 +1 -1 0.0339 28.75 2.50 MK-GR- 05 
1 +1 -1 +1 0.0339 25.25 4.00 MK-GR- 13 
1 -1 +1 +1 0.0161 28.75 4.00 MK-GR- 08 
1 0 0 0 0.0250 27.00 3.25 MK-GR- 16 
1 0 0 0 0.0250 27.00 3.25 MK-GR-17 
2 +1 -1 -1 0.0339 25.25 2.50 MK-GR-20 
2 -1 +1 -1 0.0161 28.75 2.50 MK-GR-10 
2 -1 -1 +1 0.0161 25.25 4.00 MK-GR- 07 
2 +1 +1 +1 0.0339 28.75 4.00 MK-GR- 14 
2 0 0 0 0.0250 27.00 3.25 MK-GR-18 
2 0 0 0 0.0250 27.00 3.25 MK-GR-21 
3 -1.682 0 0 0.0100 27.00 3.25 MK-GR-02 
3 +1.682 0 0 0.0400 27.00 3.25 MK-GR-04 
3 0 -1.682 0 0.0250 24.06 3.25 MK-GR-12 
3 0 +1.682 0 0.0250 29.94 3.25 MK-GR-09 
3 0 0 -1.682 0.0250 27.00 1.99 MK-GR-06 
3 0 0 +1.682 0.0250 27.00 4.51 MK-GR-15 
3 0 0 0 0.0250 27.00 3.25 MK-GR-22 
3 0 0 0 0.0250 27.00 3.25 MK-GR-01 
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Dry cell weight 
Dry cell weight, DCW, is determined using a correlation between the data 
obtained from the optical density at 600 nm (OD600) and the DCW in g/L. The optical 
density is measured using a UV spectrometer cary 50. The Varian Cary 50 UV-VIS 
spectrometer is set up at a wavelength of 600 nm. This equipment allows accurate 
measurements when absorbance is determined between 0 and 1. In consequence, 
dilutions are performed in the original sample once high cell concentration is reached in 
the fermentor vessel. The dry cell weight (DCW) is calculated after washing the cell 
resulting from the wet cell weight (WCW) calculations. Then the tubes are dried at 80°C 
for 24 hours (Inan et al 1999, Kunert et al 2008). The final correlation between dry cell 
weight and OD600 is indicated in the following equation.  
DCW (g/L) = 0.2547 (OD600) + 0.1902  (Eq. 3.1) 
The calculated DCW represents around 20% of the WCW for a total of 20 
experiments. The DCW estimated values are to be used in the determination of the 
specific yield in the final response.  
 
Figure 3.5: Linear regression to estimate relationship between DCW and OD600. 
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5P12-Rantes protein essay 
5P12-Rantes is analyzed at 280 nm of absorbance using high performance liquid 
chromatography (HPLC-Waters). A strong cation-exchange (SCX) column is used to 
perform the analysis (PolySulfoEthyl ATM, 100x4.6mm, 5 µm, 300Å, PolyLC Inc. 
104SE0503). The buffer solutions for this analysis are Mobile phase A: 50nM 2-(N-
morpholino)ethanesulfonic acid (MES) at pH 6.4, Mobile phase B: 50nM MES and 1M 
Sodium Chloride (NaCl) at pH 6.4, Mobile phase C: 0.45 µm filtered water and Mobile 
phase 40mM Ethylenediaminetetraacetic acid (EDTA). 
The HPLC passivation procedure is achieved by rinsing the installed column with 
mobile phase C and then mobile phase D at 0.1mL/min and 1.0 mL/m respectively. After 
passivation the column is rinsed with mobile phase B at 0.5ml/L and then mobile phase A 
at 1.0 mL/min.  
The SCX column is heated up to 40°C and then each sample is loaded in the 
system. The table 3.3 shows the gradient used in the HPLC system. 
Table 3.3: HPLC mobile phase gradient 
Step Time (minutes) Flow (mL/m) % A % B 
1 0 1.0 100.0 0.0 
2 2.0 1.0 100.0 0.0 
3 8.0 1.0 70.0 30.0 
4 40.0 1.0 45.0 55.0 
5 43.0 1.0 0 100.0 
6 45.0 1.0 100.0 0.0 
7 50.0 1.0 100.0 0.0 
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5P12-Rantes is eluted in the 16 and 19 minute range (Figure 3.6). Two different 
retention time reflex the existence of two forms of the protein. The 5P12-Rantes with 
pyroglutamic acid (cyclized form) at the N-terminal is eluted at 16 minutes. Meanwhile, 
the form with glutamine (un-cyclized form) at the N-terminal is eluted at 19 minutes. The 
total concentration of 5P12-Rantes is a result of the sum of the peak area of both cyclized 
and un-cyclized form. 
 
Figure 3.6: Chromatogram for quantitative analysis of 5P12-RANTES at different 
times during the methanol fed-bath phase 
Specific Yield  
The Specific yield represents the ratio of the total amount of 5P12-Rantes 
produced by each batch and the dry cell weight at the end of fermentation. The specific 
yield provides the experimenter information about the efficiency of the cell in producing 
both cyclized and un-cyclized 5P12-Rantes.  
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Results and Discussion 
Table 3.4 shows the results of the responses: The total 5P12-Rantes, the active 
form of 5P12-Rantes and the Specific yield. The first response represents the sum of the 
active and inactive form of 5P12-Rantes produced during fermentation. The active form 
of the protein represents the concentration of cyclized 5P12-RANTES in the fermentation 
broth. The specific yield is another way to measure the efficiency of the overall process.  
Table 3.5 shows the runs at which the production of 5P12-Rantes is maximized. 
These values correspond to the runs performed at the zero point.  
Table 3.6 shows the conditions at which the maximum concentration of active 
5P12-Rantes is achieved. This result shows that temperature has a important effect over 
the formation of pyro-glutamic acid.  
Even though these results shows some predictability of the responses doesn’t 
provide, by themselves, a model in which interpolation of the variables can be performed. 
The models for prediction of responses are to be evaluated using the response surface 
methodology and the central composite design. These statistical tools will provide 
equations that can be adjusted to the quantitative analysis and determine their accuracy 
and precision.   
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Table 3.4: Analytical results using SCX column 
Lot Number 
Total 5P12-
Rantes mg/L 
Active 5P12-
Rantes  mg/L 
Specific Yield 
mg Total 5P12-Rantes 
/ g Dry cell 
MK-GR- 11 40.60 17.92 0.1185 
MK-GR- 05 26.20 12.98 0.0860 
MK-GR- 13 34.85 10.13 0.0881 
MK-GR- 08 3.54 2.13 0.0102 
MK-GR- 16 55.14 29.03 0.1570 
MK-GR- 17 53.53 23.96 0.1542 
MK-GR- 20 22.43 12.50 0.0654 
MK-GR- 10 39.53 30.32 0.1104 
MK-GR- 07 21.80 3.98 0.0685 
MK-GR- 14 27.19 7.55 0.0668 
MK-GR- 18 57.08 24.49 0.1621 
MK-GR- 21 56.29 26.10 0.1524 
MK-GR- 02 22.15 9.44 0.0796 
MK-GR- 04 48.64 19.05 0.1286 
MK-GR- 12 2.12 0.84 0.0062 
MK-GR- 09 32.08 14.86 0.0989 
MK-GR- 06 0.27 0.10 0.0110 
MK-GR- 15 0.30 0.03 0.0008 
MK-GR- 22 55.81 26.35 0.1496 
MK-GR- 01 56.42 26.91 0.1735 
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Table 3.5: Experiments with high 5P12-Rantes concentration 
Block 
MeOH 
X1 
Temp 
X2 
pH 
X3 
MeOH Temp pH Id Number 
5P12-Rantes 
(mg/L) 
1 0 0 0 0.0250 27.00 3.25 MK-GR- 16 55.14 
1 0 0 0 0.0250 27.00 3.25 MK-GR- 17 53.53 
2 0 0 0 0.0250 27.00 3.25 MK-GR- 18 57.08 
2 0 0 0 0.0250 27.00 3.25 MK-GR- 21 56.29 
3 0 0 0 0.0250 27.00 3.25 MK-GR- 22 55.81 
3 0 0 0 0.0250 27.00 3.25 MK-GR- 01 56.42 
 
 
Table 3.6: Highest production of active 5P12-Rantes 
Block 
MeOH 
X1 
Temp 
X2 
pH 
X3 
MeOH Temp pH Id Number 
5P12-Rantes 
(mg/L) 
2 -1 +1 -1 0.0161 28.75 2.50 MK-GR-10 30.32 
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CHAPTER IV 
 
CALCULATIONS AND ANALISIS OF VARIANCE 
ABSTRACT 
The analysis of variance (ANOVA) is a statistical test used in the analysis of 
experimental data. The CCD model describes the behavior of the production of 5P12-
Rantes. This model is evaluated using analysis of variance. The ANOVA provides 
statistical tools to evaluate statistical hypotheses. In this context, the acceptance or 
rejection of the null hypothesis dictates the level of significance of each factor. Then, the 
alternative hypothesis is adopted if the null hypothesis is rejected (Walpole, 2007). The 
F-test is used to estimate the effect of each variable in the final response and whether or 
not the null hypothesis is rejected. The null hypothesis is rejected if the value of F-
calculated (F-calc) is higher than the F-critical (F-crit). The rejection of the null 
hypothesis implies some level of significance of the factor in the final response. The P-
value helps to discriminate between the factors that are significant from those which have 
not effect over the response. For example, a P-value lower than 0.05 indicates 
significance. The level of significance increases as the value approaches to zero. The F-
test and the P-value evaluation determine the level of significance of each factor over a 
particular response. The acceptance or rejection of the proposed model will depend on the 
statistical analysis of the responses. 
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INTRODUCTION 
The analysis of variance (ANOVA) is a statistical method used in the testing of 
statistical hypotheses. The statistical hypotheses are composed of the null hypothesis and 
the alternative hypothesis. The acceptance of rejection of the null hypothesis is based in 
the determination of value or F-calc. the F-calc represent ratio of the media square value 
of any factor and the residual error. The F-crit value is determined in the F-distribution 
probability table using the degrees of freedom of both numerator and denominator 
(Walpole, 2007). The calculation of P-value is used to evaluate the significance of each 
selected variable in the experiments. The standard value of 5% is chosen as standard 
value of significance for the evaluation of responses using ANOVA. The data obtained 
from the analytical analysis of the fermentation broth is used to perform the ANOVA 
using the software Minitab 16. 
HYPOTHESES 
The proposed equation to define the responses defines the effects of the selected variables 
(MeOHGR, T, pH). To define the response equation, X1, X2 and X3 are assigned to 
MeOHGR, T, and pH respectively. 
YTotal5P12-Rantes = µβ + β1X1 + β2X2 + β3X3 + β11X112 + β22X222 + β33X332 + β12X1X2 + 
β13X1X3 + β23X2X3           (Eq. 4.1) 
YActive 5P12-Rantes = µγ + γ1X1 + γ 2X2 + γ 3X3 + γ 11X112 + γ 22X222 + γ 33X332 + γ 12X1X2 + 
γ13X1X3 + γ 23X2X3         (Eq. 4.2) 
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YSpecific Yield =  µδ +δ1X1 + δ2X2 + δ3X3 + δ11X112 + δ22X222 + δ33X332 + δ12X1X2 + δ13X1X3 +  
δ23X2X3                 (Eq. 4.3) 
The null hypothesis state that there is not quantifiable effect of MeOHGR, T and 
pH in the overall responses 5P12-Ranres, Active 5P12-Rantes and Yield. If this 
hypothesis is true then: 
H0β : β1 = β11 = 0, β2 = β22 = 0, β3 = β33 = 0, β12 = β13 = β23 = 0  
H0γ : γ1 = γ11 = 0, γ2 = γ22 = 0, γ3 = γ33 = 0, γ12 = γ13 = γ23 = 0 
H0δ : δ1 = δ11 = 0, δ2 = δ22 = 0, δ3 = δ33 = 0, δ12 = δ13 = δ23 = 0 
The alternative hypothesis postulated that at least one of the coefficients is 
different to zero. Then: 
H1β : At least one β ≠ 0 
H1γ : At least one γ ≠ 0 
H1δ : At least one δ ≠  0 
F-TEST 
The F-test is a statistical test based on an F-distribution under the null hypothesis. 
The values obtained from the F-test will indicate the rejection or no rejection of the null 
hypothesis. F-calculated (F-calc) is determined from the ratio of the mean squares (MS) 
of factor, blocks, linear, factor squares and factor interactions and the error mean square 
(MSe). The F-critical (F-crit) is the value obtained from tables of critical values of F-
distribution using the degrees of freedom of both numerator (dfn) and denominator (dfd). 
59 
 
The rejection or not rejection of the null variable is based in the comparison of the F-calc 
and F-crit. If the value of F-calc is greater than F-crit the null hypothesis is rejected. 
Otherwise it’s not rejected. 
P-VALUE 
The P-value represents the probability of obtaining a value that is at least as the 
extreme as the calculated value if the null hypothesis is true. It has been assumed that 5% 
probability, α-value, is appropriate to evaluate the P-value. If the P-value is lower than 
the α value indicates the rejection of the null hypothesis. 
METHODS  
The RSM was analyzed using the software Minitab-16 (Minitab®). The analysis 
provides the corresponding ANOVA table for each response. Each response was 
evaluated under the null hypothesis. The ANOVA table provides the sum of squares (SS), 
the mean square (MS), the F-calc and the P-value. This analysis includes the evaluation 
for each independent factor, blocks, linear factors, quadratic factors, interaction and the 
error. The F-crit is obtained from tables of critical values F-distribution. The level of 
significance or α-value is 0.05. The data evaluated using ANOVA directs to the rejection 
of acceptance of the null hypothesis.  
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Table 4.1: ANOVA for the total amount of 5P12-Rantes with R-square = 89.01% and 3 
factors 
Source DF SS MS F-crit F-calc P-
value 
Reject 
H0β 
Blocks 2 423.49 156.58 4.46 1.45 0.290 No 
MeOH 1 181.26 181.26 5.32 1.68 0.231 No 
Temp 1 54.06 54.06 5.32 0.50 0.499 No 
pH 1 125.06 125.06 5.32 1.16 0.313 No 
MeOHGR* MeOHGR 1 60.30 301.98 5.32 2.80 0.133 No 
Temp*Temp 1 1270.54 1757.38 5.32 16.31 0.004 Yes 
pH*pH 1 4157.59 4157.59 5.32 38.58 0.000 Yes 
MeOHGR *Temp 1 29.80 29.80 5.32 0.28 0.613 No 
MeOHGR *pH 1 581.41 581.41 5.32 5.39 0.049 Yes 
Temp*pH 1 102.39 102.39 5.32 0.95 0.358 No 
Residual error 8 862.19 107.77     
Lack-of-Fit 5 860.40 172.08 9.01 287.73 0.000 Yes 
Pure error 3 1.79 0.60     
Total 19 7848.08      
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Table 4.2: ANOVA for the Active 5P12-Rantes with R-square = 86.26% and three 
factors 
Source DF SS MS F-crit F-calc P-value Reject H0γ 
Blocks 2 106.26 39.893 4.46 1.12 0.373 No 
MeOHGR 1 1.81 1.811 5.32 0.05 0.827 No 
Temp 1 75.12 75.121 5.32 2.11 0.185 No 
pH 1 183.39 183.389 5.32 5.14 0.053 No 
MeOHGR*MeOHGR 1 42.49 120.273 5.32 3.37 0.104 No 
Temp*Temp 1 276.46 382.052 5.32 10.72 0.011 Yes 
pH*pH 1 899.41 899.408 5.32 25.23 0.001 Yes 
MeOHGR *Temp 1 20.00 20.003 5.32 0.56 0.475 No 
MeOHGR *pH 1 147.32 147.319 5.32 4.13 0.077 No 
Temp*pH 1 37.45 37.455 5.32 1.05 0.335 No 
Residual error 8 285.18 35.647  
  
 
Lack-of-Fit 5 270.89 54.178 9.01 11.37 0.036 Yes 
Pure error 3 14.29 4.763     
Total 19 2074.90      
 
 
 
 
62 
 
Table 4.3: ANOVA for the Specific Yield (Total 5P12-Rantes (mg)/dry cells (g)) with R-
square = 88.07% and three factors 
Source DF SS MS F-crit F-calc P-value Reject 
H0δ 
Blocks 2 0.00166 0.00083 4.46 0.93 0.434 No 
MeOHGR 1 0.00051 0.00051 5.32 0.57 0.471 No 
Temp 1 0.01404 0.01404 5.32 15.7 0.004 Yes 
pH 1 0.00758 0.00758 5.32 8.48 0.020 Yes 
MeOHGR*MeOHGR 1 0.00233 0.00233 5.32 2.61 0.145 No 
Temp*Temp 1 0.01378 0.01378 5.32 15.41 0.004 Yes 
pH*pH 1 0.03241 0.03241 5.32 36.25 0.000 Yes 
MeOHGR*Temp 1 0.00054 0.00054 5.32 0.6 0.460 No 
MeOHGR*pH 1 0.00295 0.00295 5.32 3.3 0.107 No 
Temp*pH 1 0.00106 0.00106 5.32 1.19 0.308 No 
Residual 8 0.00715 0.00089  
  
 
Lack-of-Fit 5 0.00682 0.00136 9.01 12.15 0.033 Yes 
Pure 3 0.00034 0.00011  
  
 
Total 19    
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RESULTS AND DISCUSSION 
The tables 4.1, 4.2 and 4.3 show “lack of fit” of the model. The P-value is lower 
than the 0.01 level for the total amount of 5P2-Rantes. In addition, the P-values for both 
the active 5P12-Rantes and specific yield are at the 0.05 level of significance. The 
elevated level of significance indicates that the proposed model doesn’t accurately predict 
the responses. However, The result obtained from the significance analysis does not mean 
that the experiments are not run properly or that the data obtained is incorrect. It is more 
accurate to conclude that the responses are very complex that cannot be fit using a second 
order design. 
The evaluation of the each proposed model directs to conclude that temperature 
and pH have a great significance in the responses. Conversely, The Methanol growth rate 
(MeOHGR) does not have significant effect in the responses. In consequence, this factor is 
excluded out of the model to decrease the significance in the lack of fit.  
A new model with 2 factors at 5 levels each is proposed. Temperature and pH are 
used to evaluate the responses.  It is noticeable form tables 4.5 and 4.6 that the lack of fit 
has decreased for the active 5P12-Rantes and for the specific yield responses. However, 
table 4.4 shows that the lack of fit for the 5P12-Rantes remains significant. 
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Table 4.4: ANOVA for 5P12-Rantes with R-square of 81.24% and two factors 
Source DF SS MS F-crit F-calc P-value Reject 
H0β 
Blocks  1 16.12 16.12 6.61 0.07 0.799 No 
Temp 1 1841.60 1841.60 6.61 8.25 0.035 Yes 
pH 1 762.22 762.22 6.61 3.42 0.124 No 
Temp*Temp 1 1769.20 1769.20 6.61 7.93 0.037 Yes 
pH*pH 1 3779.43 3779.43 6.61 16.94 0.009 Yes 
Temp*pH 1 71.49 71.49 6.61 0.32 0.596 No 
Residual error 5 1115.64 223.13     
Lack-of-Fit 3 1114.16 371.39 5.41 501.16 0.002 Yes 
Pure error 2 1.48 0.74 4.46    
Total 11 5947.83      
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Figure 4.1.: Contour plot for the total 5P12-Rantes 
3
4.2
.6-50
-25
3.0
0
25
24.0
50
2.425.2 26.4 27.6 1.828.8 30.0
Total 5P12-Rantes
pH
Temp
Response Surface for Total 5P12-Rantes 
 
Figure 4.2: Surface response for the total 5P12-Rantes 
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Table 4.5: ANOVA for Active 5P12-Rantes with R-square of 85.88% and two factors 
Source DF SS MS F-crit F-calc P-value Reject 
H0β 
Blocks  1 0.25 0.250 6.61 0.01 0.939 No 
Temp 1 445.47 445.466 6.61 11.62 0.019 Yes 
pH 1 121.40 121.400 6.61 3.17 0.135 No 
Temp*Temp 1 449.38 449.381 6.61 11.72 0.019 Yes 
pH*pH 1 911.28 911.283 6.61 23.77 0.005 Yes 
Temp*pH 1 2.34 2.341 6.61 0.06 0.815 No 
Residual error 5 191.71 38.343  
  
 
Lack-of-Fit 3 178.85 59.617 5.41 9.27 0.099 No 
Pure error 2 12.86 6.431 4.46    
Total 11 1357.68      
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Figure 4.3: Contour plot for the active 5P12-Rantes 
3
4.2
.6-20
-10
0
3.0
10
20
24.0 2.425.2 26.4 27.6 1.828.8 30.0
Active 5P12-Rantes
pH
Temp
Surface Plot for Active 5P12-Rantes 
 
Figure 4.4 : response surface for the active 5P12-Rantes 
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Table 4.6: ANOVA for Active 5P12-Rantes with R-square of 81.35% and two factors 
Source DF SS MS F-crit F-calc P-value Reject 
H0β 
Blocks  1 0.000053 0.000053 6.61 0.03 0.87 No 
Temp 1 0.014738 0.014738 6.61 8.25 0.035 Yes 
pH 1 0.005794 0.005794 6.61 3.24 0.132 No 
Temp*Temp 1 0.014135 0.014135 6.61 7.91 0.037 Yes 
pH*pH 1 0.029859 0.029859 6.61 16.72 0.009 Yes 
Temp*pH 1 0.000520 0.000520 6.61 0.29 0.613 No 
Residual error 5 0.008930 0.001786  
  
 
Lack-of-Fit 3 0.008638 0.002879 5.41 19.68 0.05 No 
Pure error 2 0.000293 0.000146 4.46    
Total 11 0.047876      
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Figure 4.5: Contour plot for Specific yield 
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Figure 4.6: Surface response for specific yield 
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CHAPTER V 
RESULTS AND DISCUSSION 
The clonal linage used in this research express the un-cyclized form of 5P12-
Rantes. The formation of the active of 5P12-Rantes for is produced in the Golgi 
compartment when the translated protein is detached from the secretory signal (α-mating 
factor) by the KEX2 protease. The formation of the pyro-glutamic acid (pyro-Q) at the N-
terminal of 5P12-Rantes during fermentation is not an enzymatic reaction. The pyro-Q is 
catalyzed by temperature during fermentation (table 4.5). The cyclization reaction is not 
reversible. 5P12-Rantes protein is stable at the active form. The formation of the two 
disulfide bonds is enhanced by the P. pastoris protein disulfide isomerase.  
The results obtained from the ANOVA for each response using a second order 
model with 3 factors at 5 levels indicate “lack of fit” of the proposed models. As 
indicated previously, this lack of fit of the models indicates the complexity of the system 
in which the 5P12-Rantes expression is evaluated. The outcomes obtained from this 
analysis enable the evaluation of the effects of Methanol growth rate (MeOHGR), 
Temperature and pH. This evaluation demonstrates that MeOHGR is not a significant 
factor in the final responses. Conversely, temperature and pH have an important effect 
over the final responses. 
In order to decrease the lack of fit of the proposed models; a strategy is applied by 
decreasing the number of factors involved in the responses. Since MeOHGR has no effect 
in the final response, this factor can be excluded out of the model. Thus, a new design is 
constructed using temperature and pH. 
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The final outcome using the second order design with 2 factors at 5 levels each 
confirms the decrease in the lack of fit for both the Active 5P12-Rantes and specific yield 
responses. However, the lack of fit for the total 5P12-Rantes is recurrent and reflexes the 
complexity of the response against the proposed model. 
It is noticeable that the R-square value for the 3 responses drops from 89.01% to 
81.24% for the total 5P12-Rantes, from 86.26% to 85.88% for the Active 5P12-Rantes 
and from 88.07% to 81.35% for the specific yield. This is due to the amount of factors 
used to predict the behavior of the response.  
The models proposed to explain and predict the expression of active 5P12-Rantes 
and specific yield are: 
YActive 5P12-Rantes = - 1755.88 + 117.229 X1 + 120.224 X2 – 2.124 X112 – 16.468 X222  -  
0.584 X1X2  
YSpecific Yield =  - 10.3011 + 0.6743 X1 + 0.8306 X2 – 0.0119 X112 – 0.0943 X222 - 0.0087 
X1X2 
The optimal values for temperature and pH at which the maximum expression is 
reached determined using Minitab 16: 
Response Temperature °C pH Maximum Outcome 
Active 5P12-Rantes 27.14 3.16 26.52 g/L 
Specific yield 27.14 3.16 0.161 mg 5P12-Rantes/g cell 
74 
 
 Nevertheless the effect of methanol is disregarded from the proposed model, it is 
important to consider that a growth rate at or above 0.8 h-1 will exceed the maximum 
capacity of the cell to metabolize methanol and methanol will have detrimental effect on 
the cell growth as indicated by Zhang (2000). 
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FUTURE STUDIES 
1. Evaluate the contribution of dissolve oxygen in the responses. 
2. Evaluate the action of the enzyme glutaminyl cyclase in the formation of pyro-
glutamic acid for the active for of 5P12-Rantes during fermentation. 
 
 
 
 
 
 
 
